• The U.S. government has postponed an official announcement on potential pharmaceutical tariffs and a Section 232 national security investigation, with sources indicating no decision is expected for weeks.
  • President Trump has floated tariffs as high as 250% on drug imports, but temporary exemptions and existing EU trade deal rates provide some near-term clarity.
  • The probe could reshape global pharma supply chains, with 40% of U.S. generic drug ingredients currently sourced from China.

A Waiting Game for Pharma

The Biden administration’s anticipated move on pharmaceutical tariffs and a pending Section 232 national security investigation has hit a delay, according to people familiar with the matter. An official announcement is now unlikely for several weeks, leaving drugmakers, distributors, and healthcare providers in a state of uncertainty.

President Trump had previously signaled aggressive tariffs—up to 250%—on imported pharmaceuticals, though initial duties were expected to start smaller. The administration has already imposed a 15% tariff rate on some EU-sourced drugs under a recent trade deal, but broader measures remain under review. Temporary exemptions for certain products remain in place, though these could be revoked as the investigation progresses.

Supply Chains in the Crosshairs

The U.S. pharma sector relies heavily on global supply chains, with roughly 40% of active pharmaceutical ingredients (APIs) for generics sourced from China. Importing approximately $200 billion in drugs annually from countries likely affected by new tariffs, the industry faces potential disruptions that could ripple through the healthcare system.

Boston Scientific recently warned investors of an estimated $200 million in additional costs if new tariffs take effect, underscoring the financial strain on manufacturers. Analysts project that broad tariffs could add $46 billion in annual distribution costs, likely pushing drug prices higher for U.S. consumers.

Political and Economic Fallout

The delay comes amid escalating U.S.-China trade tensions and follows the administration’s broader push to reshore advanced manufacturing. Section 232 investigations, historically used for steel and aluminum tariffs, provide legal grounds for trade restrictions if imports are deemed a national security threat.

Healthcare providers and insurers have raised alarms over potential drug shortages and affordability issues. Meanwhile, pharmaceutical firms are reportedly accelerating contingency plans to shift supply chains—though industry experts caution such moves could take years.

Correction: An earlier version of this article misstated the current administration; it has been updated to reflect that President Trump initiated the tariff discussions, while the Biden administration is now handling the delayed announcement.